NASDAQ : ALMR
Alamar Biosciences, Inc. — Financial statements
Healthcare · Medical Instruments & Supplies · United States
Last price 30.6 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 2.12B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
Alamar Biosciences, Inc. (ALMR) reported revenue of 100.42M USD (TTM). Five years of income statement, balance sheet, cash flow and ratios below.
Income statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | |
|---|---|---|---|
| Revenue | 100.42M | 74.21M | 25.14M |
| Cost of Revenue | 41.51M | 32.51M | 16.54M |
| Gross Profit | 58.91M | 41.70M | 8.61M |
| Selling, General & Admin | 52.54M | 35.57M | 18.94M |
| Research & Development | 47.11M | 37.47M | 39.23M |
| Operating Expenses | 99.65M | 73.04M | 58.17M |
| Operating Income | -40.74M | -31.33M | -49.57M |
| Interest Expense | -754.00K | -401.00K | -2.08M |
| Interest & Investment Income | 3.16M | 2.16M | 4.67M |
| Currency Exchange Gain (Loss) | -317.00K | 421.00K | -89.00K |
| Pretax Income | -48.62M | -29.15M | -47.06M |
| Income Tax Expense | 1.04M | 665.00K | 13.00K |
| Net Income | -49.66M | -29.82M | -47.07M |
| Preferred Dividends & Other Adjustments | -804.00K | ||
| Net Income to Common | -49.66M | -29.82M | -46.27M |
| Shares Outstanding (Basic) | 23.68M | 11.55M | 10.52M |
| Shares Outstanding (Diluted) | 23.68M | 11.55M | 11.89M |
| EPS (Basic) | -2.10 | -2.58 | -4.40 |
| EPS (Diluted) | -2.10 | -2.59 | -4.60 |
| Free Cash Flow | -68.64M | -58.98M | -58.16M |
| Free Cash Flow Per Share | -2.90 | -5.11 | -4.89 |
| Gross Margin | 58.66% | 56.20% | 34.23% |
| Operating Margin | -40.57% | -42.22% | -197.15% |
| Profit Margin | -49.45% | -40.18% | -184.03% |
| Free Cash Flow Margin | -68.35% | -79.48% | -231.33% |
| EBITDA | -37.48M | -28.57M | -47.27M |
| EBITDA Margin | -37.33% | -38.50% | -188.03% |
| D&A For EBITDA | 3.26M | 2.76M | 2.29M |
| EBIT | -40.74M | -31.33M | -49.57M |
| EBIT Margin | -40.57% | -42.22% | -197.15% |
| Revenue as Reported | 100.42M | 74.21M | 25.14M |
| Advertising Expenses | 1.50M | 900.00K |
Balance sheet
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | |
|---|---|---|---|
| Cash & Equivalents | 132.97M | 30.00M | 26.77M |
| Short-Term Investments | 117.08M | 52.59M | |
| Cash & Short-Term Investments | 250.05M | 30.00M | 79.36M |
| Receivables | 20.34M | 12.75M | 7.32M |
| Inventory | 45.41M | 38.48M | 14.41M |
| Prepaid Expenses | 15.58M | 13.47M | 5.61M |
| Total Current Assets | 331.38M | 94.70M | 106.70M |
| Property, Plant & Equipment | 49.16M | 36.63M | 35.10M |
| Other Intangible Assets | 1.60M | 1.99M | 2.04M |
| Other Long-Term Assets | 8.83M | 6.67M | 5.67M |
| Total Assets | 390.98M | 139.99M | 149.51M |
| Accounts Payable | 13.79M | 5.87M | 6.19M |
| Accrued Expenses | 8.71M | 13.69M | 7.36M |
| Current Portion of Leases | 2.28M | 2.10M | 1.91M |
| Current Unearned Revenue | 2.19M | 470.00K | 575.00K |
| Other Current Liabilities | 989.00K | 1.60M | 556.00K |
| Total Current Liabilities | 27.96M | 23.73M | 16.59M |
| Long-Term Debt | 9.95M | 9.81M | |
| Long-Term Leases | 39.18M | 29.56M | 31.19M |
| Long-Term Unearned Revenue | 206.00K | 320.00K | |
| Other Long-Term Liabilities | 823.00K | 526.00K | 145.00K |
| Total Liabilities | 78.12M | 63.95M | 47.93M |
| Common Stock | 7.00K | 3.00K | 2.00K |
| Additional Paid-In Capital | 516.29M | 9.89M | 5.39M |
| Retained Earnings | -203.30M | -168.78M | -138.96M |
| Comprehensive Income & Other | -139.00K | -72.00K | 149.00K |
| Total Common Equity | 312.86M | -158.95M | -133.41M |
| Shareholders' Equity | 312.86M | 76.04M | 101.58M |
| Total Liabilities & Equity | 390.98M | 139.99M | 149.51M |
| Total Debt | 51.41M | 41.47M | 33.10M |
| Net Cash (Debt) | 198.65M | -11.47M | 46.26M |
| Net Cash Per Share | 8.39 | -0.99 | 3.89 |
| Filing Date Shares Outstanding | 69.39M | 12.05M | 11.09M |
| Total Common Shares Outstanding | 69.39M | 12.05M | 11.09M |
| Working Capital | 303.42M | 70.97M | 90.11M |
| Book Value Per Share | 4.51 | -13.19 | -12.03 |
| Tangible Book Value | 311.25M | -160.94M | -135.46M |
| Tangible Book Value Per Share | 4.49 | -13.36 | -12.21 |
| Machinery | 17.73M | 12.88M | |
| Leasehold Improvements | 1.05M | 151.00K |
Cash flow statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | |
|---|---|---|---|
| Net Income | -49.66M | -29.82M | -47.07M |
| Depreciation & Amortization | 3.26M | 2.76M | 2.29M |
| Other Amortization | 1.34M | 1.29M | 982.00K |
| Loss (Gain) From Sale of Investments | -37.00K | -122.00K | -1.89M |
| Stock-Based Compensation | 6.32M | 2.87M | 873.00K |
| Other Operating Activities | 13.45M | 1.98M | 1.59M |
| Change in Accounts Receivable | -10.88M | -5.50M | -5.10M |
| Change in Inventory | -21.35M | -23.78M | -8.75M |
| Change in Accounts Payable | 8.32M | -572.00K | 2.92M |
| Change in Other Net Operating Assets | -11.22M | -2.72M | -1.06M |
| Operating Cash Flow | -60.33M | -53.61M | -55.21M |
| Capital Expenditures | -8.31M | -5.37M | -2.95M |
| Sale (Purchase) of Intangibles | -508.00K | -1.01M | -440.00K |
| Investment in Securities | -101.55M | 52.56M | -50.55M |
| Investing Cash Flow | -110.36M | 46.18M | -53.93M |
| Long-Term Debt Issued | 10.00M | ||
| Long-Term Debt Repaid | -15.00M | ||
| Net Debt Issued (Repaid) | 60.35M | 10.00M | -15.00M |
| Issuance of Common Stock | 208.66M | 1.49M | 940.00K |
| Other Financing Activities | -981.00K | -657.00K | |
| Financing Cash Flow | 268.03M | 10.84M | 113.42M |
| Foreign Exchange Rate Adjustments | -686.00K | -172.00K | -1.00K |
| Net Cash Flow | 96.66M | 3.23M | 4.27M |
| Free Cash Flow | -68.64M | -58.98M | -58.16M |
| Free Cash Flow Margin | -68.35% | -79.48% | -231.33% |
| Free Cash Flow Per Share | -2.90 | -5.11 | -4.89 |
| Levered Free Cash Flow | -49.70M | ||
| Unlevered Free Cash Flow | -49.65M | ||
| Cash Interest Paid | 428.00K | 131.00K | 2.05M |
| Change in Working Capital | -35.14M | -32.57M | -11.99M |
Ratios
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | |
|---|---|---|---|
| Market Capitalization | 2.12B | ||
| Enterprise Value | 1.92B | ||
| Debt / Equity Ratio | 0.16 | 0.55 | 0.33 |
| Net Debt / Equity Ratio | -0.64 | 0.15 | -0.46 |
| Net Debt / EBITDA Ratio | 5.30 | -0.40 | 0.98 |
| Net Debt / FCF Ratio | 2.89 | -0.19 | 0.80 |
| Asset Turnover | 0.51 | ||
| Inventory Turnover | 1.23 | ||
| Quick Ratio | 9.67 | 1.80 | 5.22 |
| Current Ratio | 11.85 | 3.99 | 6.43 |
| Return on Equity (ROE) | -33.58% | ||
| Return on Assets (ROA) | -13.53% | ||
| Return on Capital Employed (ROCE) | -11.20% | -27.00% | -37.30% |
| Buyback Yield / Dilution | 2.89% |